Optimizing the use of vilobelimab for the treatment of COVID-19
Description
INTRODUCTION: On 4 April 2023, the United States Food and Drug Administration issued an emergency use authorization for the use of vilobelimab (Gohibic^(TM)) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of